ArticleRheumatology and immunology research2021
2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis.
Article in Rheumatology and immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- 2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.International journal of rheumatic diseases · 2026Guideline
- Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.Drug design, development and therapy · 2022Trial
- Preliminary analysis of lifestyle and genetic factors for hyperuricemia and gout prevalence in the Yunnan Miao population of China.Frontiers in genetics · 2026Article
- Clinical characteristics and risk factors of severe myelosuppression in rheumatoid arthritis patients with csDMARD non-adherence: a case series.Frontiers in pharmacology · 2026Review
- Ultrasound grayscale histogram analysis for early rheumatoid arthritis cartilage assessment.Advances in rheumatology (London, England) · 2025Article
- [Puerarin alleviates rheumatoid arthritis in rats by modulating TAK1-mediated TLR4/NF-κB signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- 25(OH)D3 and F-25(OH)D as indicators of chronic kidney disease progression in patients with rheumatoid arthritis.Scientific reports · 2025Article
- Application of 35 kDa Hyaluronic Acid Fragment in Managing Persistent Localized Pain in Rheumatoid Arthritis : A Case Report.Clinical case reports · 2025Article
- Eccentric Exercise Guidelines for Managing Rheumatoid Arthritis: Findings From a Randomized Controlled Trial.Health science reports · 2025Article
- Trends in rheumatoid arthritis burden in China and globally, 1990-2021: A longitudinal study based on the GBD database.PloS one · 2025Article
- Application of superb microvascular imaging technology in clinical disease activity of rheumatoid arthritis.Clinical rheumatology · 2024Article
- Intestinal Permeability In Subjects With Rheumatoid Arthritis: A Critical Therapeutic Priority.Integrative medicine (Encinitas, Calif.) · 2024Review
- Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on GBD 2021 data.Clinical rheumatology · 2024Article
- Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China.Immunotherapy · 2024Article
- Influence of kinesiophobia on activity, function, and anxiety levels in patients with rheumatoid arthritis.Frontiers in medicine · 2024Article
- Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.Rheumatology and therapy · 2023Article
- Unraveling the Therapeutic Mechanism ofNutrients · 2023Article
- The prognostic value of whole-genome DNA methylation in response to Leflunomide in patients with Rheumatoid Arthritis.Frontiers in immunology · 2023Article
- Management of Rheumatoid Arthritis: An Overview.Cells · 2021Review
- The Current Status and Challenges in the Diagnosis and Treatment of Rheumatoid Arthritis in China: An Annual Report of 2019.Rheumatology and immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multidisciplinary guideline development group was established to formulate this evidence-based diagnosis and treatment guidelines for rheumatoid arthritis (RA) in China. The grading of recommendations, assessment, development, and evaluation (GRADE) system was used to rate the quality of the evidence and the strength of recommendations, which were derived from research articles and guided by the analysis of the benefits and harms as well as patients' values and preferences. A total of 10 recommendations for the diagnosis and treatment of RA were developed. This new guideline covered the classification criteria, disease activity assessment and monitoring, and the role of disease modifying antirheumatic drugs (DMARDs), biologics, small molecule synthetic targeting drugs, and glucocorticoids in the treat-to-target approach of RA. This guideline is intended to serve as a tool for clinicians and patients to implement decision-making strategies and improve the practices of RA management in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.